Good news for women of a certain age: Hormone replacement therapy for menopause appears to boost the effectiveness of GLP-1 weight loss drugs like Wegovy and Zepbound, a new study says. Women using tirzepatide (Zepbound) lost more weight if they also were taking hormone therapy — 17% of body weight lost versus 14% after a median 18 months, researchers reported Saturday at the Endocrine Society’s annual meeting in San Francisco. Further, more women taking Zepbound and hormone therapy achieved at least 20% total body weight loss, with 45% meeting this goal compared to 18% of those not on hormone therapy. “These data are the first to show the combined use of tirzepatide and menopause hormone therapy significantly increases treatment effectiveness in postmenopausal women,” presenting investigator Dr. Regina Castaneda, a research fellow in endocrinology at the Mayo Clinic in Jacksonville, Fla, said in a news release. Casteneda noted that previous studies of semaglutide (Ozempic/Wegovy) yielded similar findings. “Achieving these outcomes with a second obesity medication may indicate a broader efficacy trend for pairing these two classes of medications,” Castenada said. More women are using hormone therapy to manage menopause symptoms like hot flashes and night sweats, following research that found such therapy didn’t increase risk of diseases like breast cancer and heart disease as dramatically as previously thought. Menopause-related hormone changes often result in increased belly… read on > read on >

















